Compare PARR & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PARR | ADMA |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | 2000 | 2012 |
| Metric | PARR | ADMA |
|---|---|---|
| Price | $52.53 | $8.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $70.17 | $25.67 |
| AVG Volume (30 Days) | 898.7K | ★ 3.2M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1313.56 | N/A |
| EPS | ★ 1.10 | 0.19 |
| Revenue | ★ $2,443,066,000.00 | $42,219,783.00 |
| Revenue This Year | N/A | $27.46 |
| Revenue Next Year | $3.78 | $22.11 |
| P/E Ratio | $48.62 | ★ $44.74 |
| Revenue Growth | 30.99 | ★ 43.85 |
| 52 Week Low | $26.41 | $7.21 |
| 52 Week High | $70.39 | $20.46 |
| Indicator | PARR | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 53.66 |
| Support Level | $33.67 | $7.38 |
| Resistance Level | $59.08 | $11.42 |
| Average True Range (ATR) | 2.37 | 0.32 |
| MACD | -0.22 | 0.18 |
| Stochastic Oscillator | 12.66 | 90.31 |
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments: Refining. Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operating licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.